From the publishers of JADPRO

Metastatic Triple-Negative Breast Cancer Resource Center

Advertisement

Immune-Checkpoint Inhibition for Metastatic Triple-Negative Breast Cancer: Safety First?

The approval of immune-checkpoint inhibitors (ICIs) for metastatic triple-negative breast cancer (TNBC) poses new challenges in the management of adverse events. In this article discuss the safety of ICIs in metastatic TNBC, with an emphasis on immune-related adverse events.

Nature Reviews Clinical Oncology
Advertisement
News & Literature Highlights
Advertisement
Advertisement